|
1. Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46(8): 1254-63. 2. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42(5): 692-9. 3. Zarrilli R, Casillo R, Di Popolo A, Tripodi MF, Bagattini M, Cuccurullo S, et al. Molecular epidemiology of a clonal outbreak of multidrug‐resistant Acinetobacter baumannii in a university hospital in Italy. Clin Microbiol Infect 2007; 13(5): 481-9. 4. Roberts MC. Multidrug-resistant genes are associated with an 86-kb island inAcinetobacter baumannii. Trends Microbiol 2006; 14(9): 375-8. 5. Da Silva G, Dijkshoorn L, Van Der Reijden T, Van Strijen B, Duarte A. Identification of widespread, closely related Acinetobacter baumannii isolates in Portugal as a subgroup of European clone II. Clin Microbiol Infect 2007; 13(2): 190-5. 6. Mirnejad R, Mostofi S, Masjedian F. Antibiotic resistance and carriage class 1 and 2 integrons in clinical isolates of Acinetobacter baumannii from Tehran, Iran. Asian Pac J Trop Biomed 2013; 3(2): 140-5. 7. Wright MS, Haft DH, Harkins DM, Perez F, Hujer KM, Bajaksouzian S, et al. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio 2014; 5(1): e00963-13. 8. Aleksic V, Mimica-Dukic N, Simin N, Nedeljkovic NS, Knezevic P. Synergistic effect of Myrtus communis L. essential oils and conventional antibiotics against multi-drug resistant Acinetobacter baumannii wound isolates. Phytomedicine 2014; 21(12): 1666-74. 9. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40(9): 1333-41. 10. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6(9): 589-601. 11. Michalopoulos AS ,Karatza DC. Multidrug-resistant Gram-negative infections: the use of colistin. Expert Rev Anti Infect Ther 2010; 8(9): 1009-17. 12. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007; 60(5): 1163-7. 13. Hernan RC, Karina B, Gabriela G, Marcela N, Carlos V, Angela F. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009; 65(2): 188-91. 14. Farahani RK, Moniri R, Dastehgoli K. Multi-Drug Resistant Acinetobacter-Derived Cephalosporinase and OXAs-etC Genes in Clinical Specimens of Acinetobacter spp. Isolated From Teach-ing Hospital. Jundishapur J Microbiol 2013; 6(2): 181-5. 15. Bagheri Josheghani S, Moniri R, Firoozeh F, Sehat M, Dasteh Goli Y. Susceptibility Pattern and Distribution of Oxacillinases and bla PER-1 Genes among Multidrug Resistant Acinetobacter aumannii in a Teaching Hospital in Iran. J Pathog 2015; 2015: 957259. 16. Sonne M, Jawetz E. Combined action of carbenicillin and gentamicin on Pseudomonas aeruginosa in vitro. Appl Microbiol 1969; 17(6): 893-6. 17. Ceccarelli G, Oliva A, d'Ettorre G, D'Abramo A, Caresta E, Barbara CS, et al. The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. BMC Infect Dis 2015; 15(1): 393. 18. Marie MA, Krishnappa LG, Alzahrani AJ, Mubaraki MA, Alyousef AA. A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii. Bosn J Basic Med Sci 2015; 15(4): 24-9. 19. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60(2): 317-22. 20. Temocin F, Erdinc FS, Tulek N, Demirelli M, Ertem G, Kinikli S, et al. Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii. Braz J Microbiol 2015; 46(4): 1119-24. 21. Dong X, Chen F, Zhang Y, Liu H, Liu Y, Ma L. In vitro activities of sitafloxacin tested alone and in combination with rifampin, colistin, sulbactam, and tigecycline against extensively drug-resistant Acinetobacter baumannii. Int J Clin Exp Med 2015; 8(5): 8135-40. 22. Bonapace CR, White RL, Friedrich LV, Bosso JA. Evaluation of antibiotic synergy against Acin-etobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 2000; 38(1): 43-50. 23. Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 2015; 45(1): 8-18.
|
.png){kind=logo}
